Pilot double‐blind, randomized controlled trial of short‐term atorvastatin for prevention of acute kidney injury after cardiac surgery

Prowle, John R.; Calzavacca, Paolo; Licari, Elisa; Ligabo, E. Valentina; Echeverri, Jorge; Haase, Michael; Haase-Fielitz, Anja; Bagshaw, Sean M.; Devarajan, Prasad; Bellomo, Rinaldo

doi:10.1111/j.1440-1797.2011.01546.x

Cited by 74 publications

(76 citation statements)

References 51 publications

(65 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is also true for statins. First reports on its usefulness were not supported by the following studies [168][169][170][171] . It has been known since 2001 that low-dose dopamine is not justified for the prevention and treatment of AKI [172,173] .…”

Section: Pharmacological Interventionsmentioning

confidence: 99%

Serum creatinine role in predicting outcome after cardiac surgery beyond acute kidney injury

Najafi

2014

WJC

View full text Add to dashboard Cite

Serum creatinine is still the most important determinant in the assessment of perioperative renal function and in the prediction of adverse outcome in cardiac surgery. Many biomarkers have been studied to date; still, there is no surrogate for serum creatinine measurement in clinical practice because it is feasible and inexpensive. High levels of serum creatinine and its equivalents have been the most important preoperative risk factor for postoperative renal injury. Moreover, creatinine is the mainstay in predicting risk models and risk factor reduction has enhanced its importance in outcome prediction. The future perspective is the development of new definitions and novel tools for the early diagnosis of acute kidney injury largely based on serum creatinine and a panel of novel biomarkers.

show abstract

Section: Pharmacological Interventionsmentioning

confidence: 99%

Serum creatinine role in predicting outcome after cardiac surgery beyond acute kidney injury

Najafi

2014

WJC

View full text Add to dashboard Cite

show abstract

“…Choć wstępne doniesienia (głównie retrospektywne) dokumentowały, iż osoby przyjmujące statynę cechują się mniejszym ryzykiem rozwoju AKI [59,60], to jednak wyniki badań kontrolowanych nie potwierdziły tych obiecujących obserwacji [61][62][63].…”

Section: Metody Farmakologiczneunclassified

Postępowanie w okresie okołooperacyjnym u chorych z ryzykiem wystąpienia ostrego uszkodzenia nerek, poddawanych operacjom kardiochirurgicznym

Krzych

Wybraniec²,

Chudek³

et al. 2013

Anaesthesiol Intensive Ther

View full text Add to dashboard Cite

Acute kidney injury is one of the most frequent and clinically important of all postoperative complications in cardiac surgery. It is estimated that almost half of subjects suffer from a deterioration of kidney function after a cardio-pulmonary by-pass. Renal insufficiency impacts upon the outcome in terms of an increase in postoperative morbidity and mortality, and a decrease in quality of life. Recently, a modified and unified classification of cardio-renal syndrome has been devised, which takes into account bilateral association between the heart and the kidneys. Because acute decompensation in heart function leads to acute kidney damage, therefore cardiac surgery-associated acute kidney injury may be recognised as a type 1 cardio-renal syndrome from a pathophysiological point of view. This paper aims to review the current data on the diagnosis of acute kidney injury and preventive strategies that can be implemented in cardiac surgery perioperative care.

show abstract

“…28 Conversely, a substantial amount of published data has challenged the true efficacy of statins in preventing renal injury postcardiac surgery. Prowle et al 29 randomized 100 patients undergoing cardiac surgery to atorvastatin 40 mg daily or placebo, with a follow-up of 30 months. There were no differences noted in the incidence of acute kidney injury, need for hemodialysis, or mortality.…”

Section: Patients Undergoing Cardiac Surgerymentioning

confidence: 99%

The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in renal disease

Gomez¹,

Mihos²,

Pineda³

et al. 2014

IJNRD

View full text Add to dashboard Cite

Abstract:It is well known that statins exert their main effect by inhibiting cholesterol synthesis through the inhibition of the 3-hydroxy-3-methyl-glutaryl-CoA reductase enzyme. The pleiotropic effects of statins, which are independent of their inhibition of cholesterol synthesis, have explained many of the beneficial effects of these drugs in a variety of disorders such as malignancies, infection, and sepsis, as well as in cardiovascular and rheumatologic disorders. However, the role of these drugs in renal disorders remains controversial. In the present review, we examine the most recent findings involving statins and renal disease among different clinical scenarios, including chronic kidney disease, contrast-induced nephropathy, renal injury after coronary artery bypass surgery, and renal transplant patients.

show abstract

Pilot double‐blind, randomized controlled trial of short‐term atorvastatin for prevention of acute kidney injury after cardiac surgery

Abstract: Short-term perioperative atorvastatin use was not associated with a reduced incidence of postoperative AKI or smaller increases in urinary NGAL. (ClinicalTrials.gov NCT00910221).

Cited by 74 publications

References 51 publications

Serum creatinine role in predicting outcome after cardiac surgery beyond acute kidney injury

Serum creatinine role in predicting outcome after cardiac surgery beyond acute kidney injury

Postępowanie w okresie okołooperacyjnym u chorych z ryzykiem wystąpienia ostrego uszkodzenia nerek, poddawanych operacjom kardiochirurgicznym

The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in renal disease

Contact Info

Product

Resources

About